An Open Label, Multi-Center, Safety Study of Intravitreal EBI-031, an Interleukin-6 (IL-6) Inhibitor, Administered as Single and Repeat Injections in Subjects With Diabetic Macular Edema (DME)

Trial Profile

An Open Label, Multi-Center, Safety Study of Intravitreal EBI-031, an Interleukin-6 (IL-6) Inhibitor, Administered as Single and Repeat Injections in Subjects With Diabetic Macular Edema (DME)

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs EBI 031 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Sponsors Eleven Biotherapeutics
  • Most Recent Events

    • 13 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment due to new study planned.
    • 07 Jul 2016 According to an Eleven Biotherapeutics media release, the company's Investigational New Drug (IND) application for EBI-031 for treatment of ocular diseases, has become effective.
    • 07 Jul 2016 Status changed from planning to not yet recruiting, according to an Eleven Biotherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top